4D Molecular Therapeutics (NASDAQ:FDMT) Earns "Sell (D-)" Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently commented on FDMT. Barclays reduced their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group dropped their target price on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Royal Bank of Canada decreased their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Bank of America dropped their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Finally, Chardan Capital decreased their target price on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Stock Down 2.4%

NASDAQ FDMT traded down $0.11 on Wednesday, hitting $4.39. The stock had a trading volume of 486,407 shares, compared to its average volume of 831,064. 4D Molecular Therapeutics has a one year low of $2.24 and a one year high of $28.93. The stock has a market cap of $203.37 million, a price-to-earnings ratio of -1.54 and a beta of 2.84. The company's 50-day moving average is $3.45 and its two-hundred day moving average is $4.51.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). On average, sell-side analysts anticipate that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of FDMT. KLP Kapitalforvaltning AS bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 4D Molecular Therapeutics during the fourth quarter valued at about $50,000. PNC Financial Services Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after buying an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth about $56,000. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.